Superluminal Medicines
Superluminal Medicines is a Boston-based drug discovery company using its Hyperloop™ AI platform—combining protein dynamics, generative chemistry, and cryoEM structural biology—to discover small-molecule GPCR therapeutics. It serves large pharmaceutical firms through co-development and licensing partnerships.
- Company typePrivate
- Founded2023
- HeadquartersBoston, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Superluminal Medicines does
Superluminal Medicines is a Boston-based, venture-backed drug discovery company founded in 2023 that integrates AI/ML, protein dynamics simulation, and cryoEM-based structural biology to discover small-molecule therapeutics against G protein-coupled receptors (GPCRs). The company operates its Hyperloop™ Platform, which combines proprietary Target GPS™ for predicting GPCR protein conformations (including for proteins lacking experimental structures), ADME DRIVE™ for AI/ML-based ADMET prediction, giga-scale virtual screening, generative AI for de novo molecule design, and access to multiple cryoEM microscopes for routine high-resolution structure generation. Its pipeline includes a selective, biased MC4R agonist advancing to IND-enabling studies for obesity (retained in-house) plus multiple GPCR programs (2-5) targeting cardiometabolic diseases.
The company monetizes exclusively through B2B strategic partnerships with large pharmaceutical companies, using an enterprise field-sales model and a deal structure that combines upfront payments, equity investments, development and commercial milestones, and tiered royalties on net sales. Its flagship commercial relationship is the August 2025 collaboration with Eli Lilly worth up to $1.3 billion for undisclosed GPCR targets in cardiometabolic diseases and obesity, with a secondary Axcelead DDP collaboration announced in June 2025. The company also engages in collaborative research funded by partners targeting specific GPCRs. Total equity raised is approximately $153 million ($33M seed in Aug 2023 led by RA Capital Management, $120M Series A in Sep 2024 also led by RA Capital Management), with additional strategic backers including Insight Partners, NVIDIA, Gaingels, Catalio Capital Management, and Eli Lilly.
Superluminal's primary customer segment is large pharmaceutical and biotech companies seeking differentiated AI-driven drug discovery for challenging GPCR targets. The company is headquartered at Lilly Gateway Labs in Boston, MA, is incorporated as Superluminal Medicines, Inc. in Massachusetts, and operates with a leadership team including CEO Cony D'Cruz, CSO Ajay Yekkirala, CFO Murco Ringnalda, and SVP Business Development Ryan Bloom, supported by a Scientific Advisory Board chaired by Morris J. Birnbaum. Infrastructure dependencies include Google Cloud (Vertex AI, BigQuery, Gemini), NVIDIA compute, and Rhino Federated Computing for participation in Eli Lilly's TuneLab.
Superluminal Medicines firmographics
Firmographics- Name
- Superluminal Medicines
- Legal name
- Superluminal Medicines, Inc.
- Website
- https://superluminalrx.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Superluminal Medicines is a Boston-based drug discovery company using its Hyperloop™ AI platform—combining protein dynamics, generative chemistry, and cryoEM structural biology—to discover small-molecule GPCR therapeutics. It serves large pharmaceutical firms through co-development and licensing partnerships.
- Ownership category
- akta.pro rank
Superluminal Medicines industry classification
Industry- Product category
- AI-powered drug discovery services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro industry
- Drug Discovery (Target ID/Validation & Hit Discovery)AI/ML Platforms for Drug Discovery & Experiment OptimizationHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
Keywords
Where Superluminal Medicines is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Superluminal Medicines business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Partnership and Licensing Deals: Superluminal generates revenue through strategic partnerships with pharmaceutical companies involving upfront payments, equity investments, development and commercial milestone payments, and tiered royalties on net sales of approved drugs. The company retains ownership of certain pipeline assets while granting exclusive development and commercialization rights to partners for specified targets.
- Collaborative Research Funding: Revenue from collaborative research agreements where partners fund specific drug discovery programs targeting agreed-upon GPCRs and therapeutic areas.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Superluminal Medicines product offering
Product offeringCore offering
Superluminal Medicines operates a generative biology and chemistry drug discovery business centered on its Hyperloop™ Platform, which combines AI/ML, protein dynamics, giga-scale virtual screening, generative molecule design, and cryoEM-based structural biology to identify and develop small-molecule therapeutics against G protein-coupled receptors (GPCRs). The company delivers these capabilities through strategic co-development and licensing partnerships with large pharmaceutical companies, retaining rights to selected pipeline assets such as its biased MC4R agonist for rare genetic obesity.
Product overview
Superluminal Medicines operates as a drug discovery company built around its Hyperloop™ Platform—an integrated computational and experimental suite that unifies protein dynamics prediction (Target GPS™), generative AI molecule design, giga-scale virtual screening, and ADMET profiling (ADME DRIVE™). The platform supports a pipeline of small-molecule GPCR-targeted drug candidates, including a biased MC4R agonist advancing toward IND filing and multiple programs in lead optimization targeting cardiometabolic diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- Hyperloop™ Platform Integrated computational and experimental drug discovery platform combining AI/ML, protein dynamics simulation, giga-scale virtual screening, generative molecule design, ADMET prediction, and cryoEM structural biology to discover small-molecule therapeutics against GPCRs. Used in-house and with pharma partners such as Eli Lilly.
- Target GPS™ Proprietary AI/ML method that predicts protein conformations and creates dynamic ensemble models of GPCRs in days rather than months, including for proteins that lack experimental structures. Supports structure-based drug design within the Hyperloop™ platform.
- ADME DRIVE™ AI/ML-based ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) prediction tools that enable earlier and more accurate candidate selection by combining public, private, and proprietary data sources.
- MC4R Program (biased MC4R agonist for obesity) Wholly owned small-molecule program: a selective, biased melanocortin 4 receptor (MC4R) agonist designed to activate only relevant MC4R signaling pathways, offering a broad therapeutic window while avoiding side effects. Advancing to IND-enabling studies for obesity, including rare genetic obesity forms.
- GPCR Pipeline Programs (cardiometabolic small molecules) Portfolio of small-molecule GPCR-targeted discovery programs spanning multi-functional ligands, PAMs/NAMs, and antagonists aimed at cardiometabolic diseases, blending scientific innovation with patient-centric precision medicine.
Quantifiable outcome
- Routinely generates dozens of high-resolution proprietary protein structures per month
- +2 more outcomes
Companies that use Superluminal Medicines
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Superluminal Medicines technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature6 records
Superluminal Medicines partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered supporting, flagship and core.
- Rhino Federated ComputingsupportingProvides federated computing technology enabling Superluminal to participate in Eli Lilly's TuneLab platform, allowing collaborative AI model training without sharing raw proprietary data.
- Eli Lilly and CompanyflagshipUp to $1.3 billion collaboration to discover and develop small-molecule drugs targeting undisclosed GPCRs for cardiometabolic diseases and obesity. Deal includes upfront payments, equity investment, development and commercial milestones, and tiered royalties on net sales. Superluminal retains a lead MC4R program for rare genetic obesity while Lilly gains exclusive rights to other candidates.
- Axcelead DDPcoreCollaboration on drug discovery targeting specific molecular mechanisms, continuing a productive relationship between the two companies for joint drug discovery efforts.
- Google CloudcoreSuperluminal leverages Google Cloud's infrastructure including Vertex AI Model Garden, BigQuery, and Gemini model capabilities for molecule generation, drug repurposing, and synthetic data creation as part of their AI-driven drug discovery pipeline.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Superluminal Medicines competitors and assessment
Company assessmentEmerging players
- Cradle Bio: AI-driven protein engineering platform using generative models to design novel biologics; adjacent in AI drug discovery approach though focused on protein design rather than GPCR small molecules.
- Generate Biomedicines: Generative AI biology platform for novel protein therapeutics; overlaps in AI-driven drug discovery methodology though focused on biologics rather than small molecules.
Broad incumbents
- Eli Lilly Catalyze360: Eli Lilly's externalized R&D arm that partners with AI-driven discovery companies including Superluminal; represents the customer/incumbent side of the AI drug discovery partnership model.
Direct peers
- Schrödinger: Computational drug discovery platform combining physics-based simulation with ML for small molecule discovery; partners with pharma on structure-based and AI-driven programs targeting similar audiences as Superluminal.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with ML to identify novel therapeutics; targets similar pharma partnership model with platform-based small molecule and biologic programs.
- Exscientia: AI-driven precision medicine company using generative AI to design novel small molecules; competes directly in pharma partnership and pipeline development model focused on challenging targets.
- Insitro: Machine learning-driven drug discovery company combining high-throughput biology with predictive models to accelerate small molecule and biologic pipeline development for pharma partners.
- Atomwise: AI-driven small molecule discovery company using structure-based virtual screening and ML to identify leads; partners with pharma and pursues proprietary pipeline across multiple therapeutic areas.
- Isomorphic Labs: Alphabet-backed AI drug discovery company applying deep learning to predict protein structures and design small molecules; targets similar pharma partnership opportunities with deep-pocketed backers.
- Iambic Therapeutics: AI-driven drug discovery company combining physics-based and ML approaches to design small molecule therapeutics; pursues similar pharma partnership model and proprietary pipeline development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Superluminal Medicines social profiles
Digital presenceSuperluminal Medicines financial estimates
Financial estimateRevenue estimate
Valuation estimate
Superluminal Medicines leadership team
Management profileNumber of profiles
Profiles9 records
Superluminal Medicines funding detail
Funding detailFunding overview
Funding rounds5 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Superluminal Medicines M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Superluminal Medicines
What does Superluminal Medicines do?
Superluminal Medicines operates a generative biology and chemistry drug discovery business centered on its Hyperloop™ Platform, which combines AI/ML, protein dynamics, giga-scale virtual screening, generative molecule design, and cryoEM-based structural biology to identify and develop small-molecule therapeutics against G protein-coupled receptors (GPCRs). The company delivers these capabilities through strategic co-development and licensing partnerships with large pharmaceutical companies, retaining rights to selected pipeline assets such as its biased MC4R agonist for rare genetic obesity.
Is Superluminal Medicines a public or private company?
Superluminal Medicines is a private company. It is classified as venture growth investor backed and is currently operating.
When was Superluminal Medicines founded?
Superluminal Medicines was founded in 2023. It employs 51 to 100 people.
Where is Superluminal Medicines based?
Superluminal Medicines is headquartered in Boston, United States, in the North America region.
How does Superluminal Medicines make money?
Two revenue lines are on record. Partnership and Licensing Deals are the primary driver. The others are collaborative Research Funding.
Who are Superluminal Medicines's main competitors?
Emerging players on record are Cradle Bio and Generate Biomedicines. Eli Lilly Catalyze360 is listed as a broad incumbent. Direct peers are Schrödinger, Recursion Pharmaceuticals, Exscientia, Insitro, Atomwise, Isomorphic Labs and Iambic Therapeutics.
Does Superluminal Medicines have an API?
No public API is recorded for Superluminal Medicines.
What industry is Superluminal Medicines in?
Superluminal Medicines's product category is AI-powered drug discovery services. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2834.